Differential pulsatile secretagogue control of GH secretion in healthy men.
Norman. Catalina C; Miles. John J; Bowers. Cyril Y CY; Veldhuis. Johannes D JD
Key Findings
- Testosterone supplementation roughly doubled GH pulse amplitude when GHRH was given with saline.
- Higher testosterone levels were linked to larger GH pulses across several test conditions.
- Higher BMI reduced the GH‑boosting effect of GHRP‑2, while higher estradiol increased overall GH levels during GHRP‑2 infusion.
Practical Outcomes
- For biohackers using GHRP‑2, maintaining a lean body (low BMI) and ensuring adequate testosterone/estradiol may enhance GH spikes. Combining GHRP‑2 with testosterone therapy or natural testosterone‑boosting strategies could be more effective, especially in older men. However, the protocol was an IV infusion in a controlled lab, so real‑world dosing will need careful translation.
Summary
In older men, giving the GH‑releasing peptide GHRP‑2 together with testosterone or higher estradiol levels boosts the natural, pulse‑like spikes of growth hormone (GH). Leaner men (lower BMI) also see a stronger GH response to GHRP‑2. The study shows that hormone balance and body composition shape how well GHRP‑2 works.
Abstract
Pulsatile growth hormone (GH) secretion putatively reflects integrated regulation by GH-releasing hormone (GHRH), somatostatin (SST), and GH-releasing peptide (GHRP). GHRH and SST secretion is itself pulsatile. However, how GHRH and SST pulses act along with GHRP to jointly determine pulsatile GH secretion is unclear. Moreover, how testosterone (T) modulates such interactions is unknown. These queries were assessed in a prospectively randomized, placebo-controlled double-blind cohort comprising 26 healthy older men randomized to testosterone (T) vs. placebo supplementation. Pulses of GHRH, SST, or saline were infused intravenously at 90-min intervals for 13 h, along with either continuous saline or ghrelin analog (GHRP-2). The train of pulses was followed by a triple stimulus (combined l-arginine, GHRH, and GHRP-2) to estimate near-maximal GH secretion over a final 3 h. Testosterone vs. placebo supplementation doubled pulsatile GH secretion during GHRH pulses combined with continuous saline (GHRH/saline) (P < 0.01). Pulsatile GH secretion correlated positively with T concentrations (270-1,170 ng/dl) in the 26 men during saline pulses/saline (P = 0.015, R(2) = 0.24), GHRH pulses/saline (P = 0.020, R(2) = 0.22), and combined GHRH pulses/GHRP-2 (P = 0.016, R(2) = 0.25) infusions. Basal nonpulsatile GH secretion correlated with T during saline pulses/GHRP-2 drive (P = 0.020, R(2) = 0.16). By regression analysis, pulsatile GH secretion varied negatively with body mass index (BMI) during saline/GHRP-2 infusion (P = 0.001, R(2) = 0.36), as well as after the triple stimulus preceded by GHRH/GHRP-2 (P = 0.013, R(2) = 0.23). Mean (10-h) GH concentrations under GHRP-2 were predicted jointly by estradiol (positively) and BMI (negatively) (P < 0.001, R(2) = 0.520). These data indicate that estradiol, T, and BMI control pulsatile secretagogue-specific GH-regulatory mechanisms in older men.
Study Information
pubmed
2013
2013-03-13T00:00:00.000Z
10.1152/ajpregu.00069.2013
4
42